Cumulus is the first oncology Biotech creation studio in Europe, with an interesting business model that affords a high level of diversity and flexibility in the roles we create. The company provides an exciting opportunity for individuals to join a team of seasoned experts.
With ambitious growth plans, Cumulus is anticipating recruitment across multiple levels in 2023 and beyond to support the spinout companies it creates, including leadership positions and more junior roles where there will be opportunity to learn and develop skills in company start-up processes. Cumulus operates in a dynamic, collaborative and inclusive environment. If you think you have relevant skills and are passionate about scientific integrity, entrepreneurship and making an impact to quality of life on a global scale we would be delighted to hear from you.
Senior Administration Assistant to the Executive team
Working at Cumulus Oncology is never repetitive - there is always something new to learn and new to explore. The team take a genuine interest in you succeeding and every day I am grateful to work alongside some of the brightest and most experienced minds in oncology and drug development.
Dr Ian Waddell
Chief Scientific Officer
I love working in the Cumulus Oncology environment - it’s fast paced and challenging but the dynamic decision-making means that it feels like we are always making progress towards our goals. I have always wanted to make a difference for patients through designing and developing new and novel therapeutic entities and Cumulus certainly helps me achieve that ambition. Also, despite our disparate locations throughout Europe, the team is hugely supportive, and this makes for a very flexible working pattern that allows for life outside work.
Working with smart, experienced people who you enjoy collaborating with makes being in oncology drug development a pleasure; Cumulus Oncology is unique in offering such an environment.
Get in touch
We are interested in talking with asset holders from different sectors, including Universities, Drug Discovery groups as well as Biotech and Pharma companies re-prioritising their oncology portfolio.